Bio-Rad Laboratories (BIO) Q2 2026 Earnings Report

The call showed a mix of encouraging operational and strategic progress alongside meaningful near-term headwinds. Positives include a strong sequential recovery (Q2 up ~10% vs Q1), clinical diagnostics returning to growth (+8.3% CC), ddPCR momentum (6% revenue growth, >20% instrument growth), improved sequential operating performance, and disciplined capital actions (Stilla acquisition accretive, $32M buyback, $30–35M annualized cost savings target). Offsetting these are persistent Life Science weakness (-5.1% CC), a steep decline in China (high-teens), consumables pull-through lag, process chromatography lumpiness, higher SG&A and logistics costs, and a cautious full-year revenue framework that allows for modest contraction. Overall, positives and negatives are roughly balanced: strategic momentum and margin recovery are clear, but near-term top-line and region-specific headwinds temper the outlook.

Bio‑Rad reaffirmed full‑year 2026 non‑GAAP guidance of currency‑neutral revenue growth of -3.0% to +0.5% (Life Science -3% to -1%; Clinical Diagnostics -3% to +1%), with Q3 revenue expected flat to Q2 (Q2 ≈ $651M) and a sequential mid‑single‑digit percentage ramp from Q3 to Q4; full‑year non‑GAAP gross margin is guided to 53%–54% and non‑GAAP operating margin to 10%–12%. The company reiterated 2026 free cash flow of ~$290M–$340M, noted ~ $206M of buyback capacity remaining as of June 30, and incorporated an estimated ~$4M China/order‑timing headwind for the back half plus a tougher process‑chromatography comp and elevated freight/logistics as near‑term drags; it expects a modest sequential step‑up in SG&A and R&D in Q3. Bio‑Rad also announced a restructuring targeting $30M–$35M of net annualized savings (one‑time costs ≈ $90M), with minimal 2026 savings, most savings realized by end‑2027 and an estimated ~40–50 bps operating‑margin expansion in 2027.